Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers

Applied Health Economics and Health Policy

Volumn 12, Issue 3, 2014, Pages 231-238

  Carlson, Josh J ^a   Gries, Katharine S ^a   Yeung, Kai ^a   Sullivan, Sean D ^a   Garrison, Louis P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; HEALTH CARE CONCEPTS; HEALTH INSURANCE; HEALTHCARE PAYER; HUMAN; MANAGED CARE ORGANIZATION; MARKETING; NAMED GROUPS OF PERSONS; NATIONAL HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PATIENT ASSESSMENT; PATIENT CARE; PERFORMANCE BASED RISK SHARING ARRANGEMENT; PRESCRIPTION; REIMBURSEMENT; REVIEW; RISK MANAGEMENT; DEVICES; ECONOMICS; HEALTH CARE COST; PROCEDURES; TRENDS;

EQUIPMENT AND SUPPLIES; HEALTH CARE SECTOR; HUMANS; REIMBURSEMENT MECHANISMS; REIMBURSEMENT, INCENTIVE; RISK SHARING, FINANCIAL;

EID: 84901661562     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0093-x     Document Type: Review

References (24)

1. Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96(3): 179-90. doi:10.1016/j.healthpol.2010.02.005.
2. de Pouvourville G. Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ. 2006; 7(3):155-7.
3. Espin J, Rovira J, A Olry de Labry. WHO/HAI Project on Medicine Prices and Availability. Review Series on Pharmaceutical Pricing Policies and Interventions. Working Paper 1: external reference pricing. Geneva: World Health Organization and Health Action International; 2011.
4. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570-9. doi:10.1016/j.jval.2011.12.013.
5. Louis P, Garrison J, Towse A, Briggs A. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: ISPOR good practices for performance-based risk-sharing arrangements task force report. Value Health. 2013;16(5):703-19.
6. NICE. Citizens Council report on "only in research"- questionnaire. 2007. http://www.nice.org.uk/media/129/29/OIRReport300407.pdf. Accessed 15 Aug 2012.
7. The Pharmaceutical Price Regulation Scheme. 2009. http://webarchive. nationalarchives.gov.uk/20130107105354/http://dh.gov.uk/health/category/ policy-areas/nhs/medicines-nhs/pprs/. Accessed 3 Dec 2012.
8. NHS. A new value-based approach to the pricing of branded medicines. London: Department of Health, Medicines, Pharmacy & Industry Group; 2010.
9. National Institute for Health and Care Excellence. List of technologies with approved patient access schemes, recommended by NICE for use in the NHS. 2013. http://www.nice.org.uk/aboutnice/howwework/paslu/ ListOfPatientAccessSchemesApprovedAsPartOfANICEAppraisal.jsp. Accessed 23 Jul 2013.
10. International Society for Pharmacoeconomics and Outcomes Research. ISPOR global health care systems road map. 2013. http://www.ispor.org/HTARoadMaps/ Default.asp. Accessed 1 Jun 2013.
11. Agenzia Italiana del Farmaco. Registri Farmaci sottoposti a monitoraggio. 2014. http://www.agenziafarmaco.gov.it/it/content/registri-farmaci-sottoposti- monitoraggio. Accessed 15 Jan 2014.
12. Carlson JJ, Garrison LP Jr, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm. 2009;15(8):683-7.
13. Center for Medicare and Medicaid Services. Coverage with evidence development. Centers for Medicare & Medicaid Services; 2008. http://www.cms.hhs.gov/CoverageGenInfo/03-CED.asp. Accessed 8 Apr 2008.
14. Australian Government: Department of Health and Ageing. Step 7: entering agreements to share risk. 2012. http://www.pbs.gov.au/info/industry/listing/ listing-steps/g-entering-agreements. Accessed 5 Aug 2012.
15. Wonder M, Backhouse ME, Sullivan SD. Australian managed entry scheme: a new manageable process for the reimbursement of new medicines? Value Health. 2012;15(3):586-90. doi:10.1016/j.jval.2012.02.004.
16. Australian Government: Department of Health and Ageing. Memorandum of understanding with medicines Australia. 2010. http://www.pbs.gov.au/info/ industry/useful-resources/memorandum. Accessed 8 Jul 2013.
17. Gress S, Niebuhr D, May U, Wasem J. Reform of prescription drug reimbursement and pricing in the German social health insurance market: a comparison of three scenarios. Pharmacoeconomics. 2007;25(6):443-54. (Pubitemid 46849186)
18. Mennenoeh H. Pharmaceutical and biotechnology update. Hogan & Hartson LLP. 2008. http://www.hoganlovells.com/files/Publication/e231044e-f929-498f- a7cb-d93e15b10234/Presentation/PublicationAttachment/2eb2c6ee-72f4-4b99-8f2f- ddb7c56ac828/PharmaBiotech.pdf. Accessed 21 Jan 2013.
19. Drug Commission of the German Medical Association. Opinion on the "cost-sharing initiatives" and "risk-sharing agreements" between pharmaceutical manufacturers and Health and Hospital [in German]. 2008. http://www.akdae.de/Stellungnahmen/Weitere/20080508.pdf. Accessed 21 Jan 2013.
20. Senior M. Is France creating its own NICE? 2012. http://www. realendpoints.com/is-france-creating-its-own-nice. Accessed 23 Jul 2013.
21. Chicoye A, editor. Evidence generation via conditional coverage for medical technologies - what kind of evidence should be generated to support access to relevant innovations? ISPOR 15th Annual European Congress; 3-7 Nov 2012; Berlin.
22. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer. 2013. doi:10.1002/cncr.28321.
23. National Institute of Health and Care Excellence. Final appraisal determination: gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. London: NICE; 2010.
24. McCabe CJ, Stafinski T, Edlin R, Menon D. Access with evidence development schemes: a framework for description and evaluation. Pharmacoeconomics. 2010;28(2):143-52. doi:10.2165/11530850-000000000-00000.